×
验证码:
换一张
忘记密码?
记住我
CORC
首页
科研机构
检索
知识图谱
申请加入
托管服务
登录
注册
在结果中检索
科研机构
中国医学科学院 北... [18]
复旦大学上海医学院 [16]
金属研究所 [3]
山东大学 [2]
中南大学 [2]
吉林大学白求恩第一医... [2]
更多...
内容类型
期刊论文 [41]
会议论文 [8]
发表日期
2021 [1]
2020 [1]
2019 [4]
2018 [12]
2017 [7]
2016 [10]
更多...
学科主题
Materials ... [1]
Metallurgy... [1]
×
知识图谱
CORC
开始提交
已提交作品
待认领作品
已认领作品
未提交全文
收藏管理
QQ客服
官方微博
反馈留言
浏览/检索结果:
共49条,第1-10条
帮助
已选(
0
)
清除
条数/页:
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
排序方式:
请选择
作者升序
作者降序
题名升序
题名降序
发表日期升序
发表日期降序
提交时间升序
提交时间降序
Improving oxidation resistance of gamma-TiAl based alloy by depositing TiAlSiN coating: Effects of silicon
期刊论文
CORROSION SCIENCE, 2021, 卷号: 179, 页码: 12
作者:
Zhang, Kai
;
Xin, Li
;
Lu, Yiliang
;
Cheng, Yuxian
;
Wang, Xiaolan
收藏
  |  
浏览/下载:17/0
  |  
提交时间:2021/03/15
A. Intermetallic
A. Ceramic coating
B. STEM
B. Thermal cycling
C. Oxidation
Cyclic oxidation behaviour of Ti/TiAlN composite multilayer coatings deposited on titanium alloy
期刊论文
CORROSION SCIENCE, 2020, 卷号: 166
作者:
Zhang, Mingming
;
Cheng, Yuxian
;
Xing, Li
;
Su, Jianxiu
;
Li, Yongfeng
收藏
  |  
浏览/下载:25/0
  |  
提交时间:2021/02/03
Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial
期刊论文
ONCOLOGIST, 2019, 卷号: 24, 期号: 8
作者:
Zhou, Ai-Ping
;
Bai, Yuxian
;
Song, Yan
;
Luo, Hong
;
Ren, Xiu-Bao
收藏
  |  
浏览/下载:31/0
  |  
提交时间:2019/12/05
Anlotinib
Metastatic renal cell cancer
Phase II clinical trial
Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial
期刊论文
ONCOLOGIST, 2019, 卷号: 24, 期号: 8, 页码: E702-E708
作者:
Zhou, Ai-Ping
;
Bai, Yuxian
;
Song, Yan
;
Luo, Hong
;
Ren, Xiu-Bao
收藏
  |  
浏览/下载:27/0
  |  
提交时间:2019/12/11
Anlotinib
Metastatic renal cell cancer
Phase II clinical trial
Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial
期刊论文
2019, 卷号: 24, 期号: 8, 页码: E702-E708
作者:
Zhou, Ai-Ping
;
Bai, Yuxian
;
Song, Yan
;
Luo, Hong
;
Ren, Xiu-Bao
收藏
  |  
浏览/下载:18/0
  |  
提交时间:2020/01/03
Anlotinib
Metastatic renal cell cancer
Phase II clinical trial
Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial
期刊论文
2019, 卷号: 39, 期号: 1, 页码: 16
作者:
Huang, Jing
;
Xu, Binghe
;
Liu, Ying
;
Huang, Junxing
;
Lu, Ping
收藏
  |  
浏览/下载:31/0
  |  
提交时间:2020/01/03
Esophageal squamous cell carcinoma
Recurrent
Metastasis
Multicenter
open-label
randomized trial
Irinotecan
S-1
Overall survival
Progression-free survival
Objective response rate
Disease control rate
Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial
期刊论文
JOURNAL OF CLINICAL ONCOLOGY, 2018, 卷号: 36, 期号: 30
作者:
Qin, Shukui
;
Li, Jin
;
Wang, Liwei
收藏
  |  
浏览/下载:4/0
  |  
提交时间:2019/12/04
Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial
期刊论文
JOURNAL OF CLINICAL ONCOLOGY, 2018, 卷号: 36, 期号: 30
作者:
Xiong, Jianping
;
Qin, Shukui
;
Li, Jin
;
Wang, Liwei
;
Xu, Jianming
收藏
  |  
浏览/下载:6/0
  |  
提交时间:2019/12/05
Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer The FRESCO Randomized Clinical Trial
期刊论文
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 卷号: 319, 期号: 24
作者:
Cheng, Ying
;
Li, Jin
;
Qin, Shukui
;
Xu, Rui-Hua
;
Shen, Lin
收藏
  |  
浏览/下载:26/0
  |  
提交时间:2019/12/05
Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer
期刊论文
INVESTIGATIONAL NEW DRUGS, 2018, 卷号: 36, 期号: 2
作者:
Ouyang, Xuenong
;
Shi, Meiqi
;
Jie, Fangwei
;
Bai, Yuxian
;
Shen, Peng
收藏
  |  
浏览/下载:28/0
  |  
提交时间:2019/12/05
Phase III
Dulanermin
NSCLC
Progression-free survival
Objective response rate
©版权所有 ©2017 CSpace - Powered by
CSpace